Cargando…

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style

The receptor for the urokinase plasminogen activator (uPAR) is up-regulated in malignant tumors. Historically the function of uPAR in cancer cell invasion is strictly related to its property to promote uPA-dependent proteolysis of extracellular matrix and to open a path to malignant cells. These fea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margheri, Francesca, Luciani, Cristina, Taddei, Maria Letizia, Giannoni, Elisa, Laurenzana, Anna, Biagioni, Alessio, Chillà, Anastasia, Chiarugi, Paola, Fibbi, Gabriella, Rosso1, Mario Del
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039230/ https://www.ncbi.nlm.nih.gov/pubmed/24681666

Ejemplares similares

Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis
por: Chillà, Anastasia, et al.
Publicado: (2018)

uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines
por: Biagioni, Alessio, et al.
Publicado: (2020)

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019)

Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme
por: Laurenzana, Anna, et al.
Publicado: (2014)

Differential uPAR recruitment in caveolar-lipid rafts by GM1 and GM3 gangliosides regulates endothelial progenitor cells angiogenesis
por: Margheri, Francesca, et al.
Publicado: (2015)

uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells
por: Biagioni, Alessio, et al.
Publicado: (2020)

CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines
por: Biagioni, Alessio, et al.
Publicado: (2021)

Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling
por: Chillà, Anastasia, et al.
Publicado: (2023)

uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells
por: Andreucci, Elena, et al.
Publicado: (2022)

Publisher Correction to: delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2019)

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma
por: Chillà, Anastasia, et al.
Publicado: (2020)

Delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2018)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

Type II CRISPR/Cas9 approach in the oncological therapy
por: Biagioni, A., et al.
Publicado: (2017)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
por: Skovgaard, Dorthe, et al.
Publicado: (2016)

Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells
por: Taddei, Maria Letizia, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer
por: Illemann, Martin, et al.
Publicado: (2014)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
por: Zhao, Baoyu, et al.
Publicado: (2015)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
por: Leth, Julie Maja, et al.
Publicado: (2021)

Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2022)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression
por: Ciavarella, S, et al.
Publicado: (2017)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Tumor-tropic endothelial colony forming cells (ECFCs) loaded with near-infrared sensitive Au nanoparticles: A “cellular stove” approach to the photoablation of melanoma
por: Margheri, Giancarlo, et al.
Publicado: (2016)

Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma
por: Semina, Ekaterina V., et al.
Publicado: (2020)

Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
por: Sorio, Claudio, et al.
Publicado: (2011)

Author Correction: Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2023)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ducc02go18an7rk4o4rckuk8bf